Stroke biomarkers – the search for a rapid predictive test
This article was originally published in Clinica
Stroke is the third leading cause of death in the US, and its cost to the country's healthcare system totalled $68.9bn in 2009, according to the American Heart Association. Timely and accurate diagnosis of stroke is critical to improving treatment. In this article, Phil Greenfield reports on the progress made in stroke biomarker research and the development of a truly predictive, rapid blood test
You may also be interested in...
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you would like to see in the format of the content or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.